Annovis Bio files three new patents for combination therapies

Annovis Bio announced the filing of three new patents for combination therapies involving its lead compound, buntanetap. These patents cover combinations of buntanetap with Trulicity, Viagra, or a combination of all three, creating a multifaceted approach to treating neurodegenerative diseases. Buntanetap, the Company’s lead drug asset, inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients. Recent preclinical studies have demonstrated that when buntanetap is combined with a GLP-1 agonist or PDE5 inhibitors, cognitive function in Alzheimer’s mouse models improves to levels beyond those observed in healthy controls. With these compelling results demonstrating strong potential for cognition-enhancing combinations, Annovis further strengthens its intellectual property portfolio through the filing of the following patents: Buntanetap + Trulicity. Buntanetap + Viagra. Buntanetap + Trulicity + Viagra.